• Merck reported Phase 3 KEYNOTE-C93 met its primary endpoint, with Keytruda monotherapy improving PFS versus carboplatin-paclitaxel in dMMR advanced or recurrent endometrial cancer.
• Interim overall survival analysis showed a favorable trend for Keytruda, though data were not mature; the trial continues with a future OS readout planned.
• Trial enrolled 299 patients; Keytruda dosed 400 mg every six weeks for up to 18 cycles versus six cycles of platinum-doublet chemotherapy.
• Merck plans to present results at a medical meeting, then share data with regulators; no new safety signals were identified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260715484958) on July 15, 2026, and is solely responsible for the information contained therein.